Background: Chromogranin A is the major protein co-stored and co-released with catecholamines from secretory vesicles in adrenal medulla and postganglionic sympathetic axons. It is required for formation of catecholamine secretory vesicles in chromaffin cells and its expression may be sufficient even to induce a regulated secretory system in non-secretory cells. It is also a pro-hormone that gives rise to biologically active peptides such as the dysglycemic peptide pancreastatin, the antimicrobial peptide chromacin, the vasodilator vasostatin, and catestatin that acts to inhibit catecholamine release.
Positive Control: Human small bowel tissue.
Immunogen: Synthetic peptide derived from human Chromogranin A protein.
Purification Method: Antigen Immunoaffiinity Purification.
Formulation: Provided as solution in phosphate buffered saline with 0.08% sodium azide.
References: 1. Konecki, D.S., et al. ‘The primary structure of human chromogranin A and pancreastatin’ J. Biol. Chem., 262, 17026-17030 (1987)
2. Pasqua, T., et al. ‘Full-length human chromogranin-A cardioactivity: myocardial, coronary, and stimulus-induced processing evidence in normotensive and hypertensive male rat hearts.’ Endocrinology, 154, 3353-3365 (2013)
3. Chen, Y., et al. ‘Naturally occurring genetic variants in human chromogranin A (CHGA) associated with hypertension as well as hypertensive renal disease.’ Cell Mol. Neurobiol., 30, 1395-1400 (2010)
4. Mahapatra, N.R., et al. ‘Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog.’ J. Clin. Invest., 115, 1942-1952 (2005)
5. Mahata, S.K., et al. ‘Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist.’ J. Clin. Invest., 100, 1623-1633 (1997).
UniProt: P10645.
Caution: This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals.
English
Deutsch
